Related Experiment Videos
Takayasu arteritis: follow-up studies for 20 years
1Third Department of Internal Medicine, Tokyo Medical and Dental University, School of Medicine, Japan.
Heart and Vessels. Supplement
|January 1, 1992
Summary
Takayasu arteritis patients with the Bw52 antigen showed more severe inflammation and a higher incidence of aortic regurgitation. Treatment with steroids and antiplatelet therapy significantly reduced inflammatory markers in patients with this condition.
Area of Science:
- Cardiology
- Immunology
- Rheumatology
Background:
- Takayasu arteritis is a rare, chronic inflammatory disease affecting large arteries.
- The role of human leukocyte antigen (HLA) Bw52 in Takayasu arteritis pathogenesis and clinical presentation requires further elucidation.
Purpose of the Study:
- To investigate the association between HLA Bw52 antigen and clinical manifestations, disease severity, and treatment response in Takayasu arteritis patients.
- To analyze the impact of HLA Bw52 on inflammatory markers and cardiovascular complications.
Main Methods:
- Retrospective review of 126 Takayasu arteritis patients treated between 1971 and 1990.
- HLA typing, arteriography, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), lung scintigraphy, and echocardiography were utilized.
Main Results:
- 47% of patients carried the Bw52 antigen, significantly higher than in healthy Japanese individuals.
- Bw52 positive patients exhibited more severe inflammatory conditions, higher rates of aortic regurgitation (73% vs 23%), and required higher steroid doses for longer durations.
- Treatment led to significant reductions in CRP and ESR levels.
Conclusions:
- The Bw52 antigen is strongly associated with Takayasu arteritis in the Japanese population.
- HLA Bw52 positivity correlates with increased disease severity, specific vascular involvement, and a higher risk of aortic regurgitation.
- These findings suggest a genetic predisposition influencing disease phenotype and potentially treatment strategies.